Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis
Raja Atreya(Friedrich-Alexander-Universität Erlangen-Nürnberg), C J Hawkey(NIHR Nottingham Digestive Diseases Biomedical Research Unit), Milan Lukáš(Charles University), Ursula Seidler(Medizinische Hochschule Hannover), Markus F. Neurath(Friedrich-Alexander-Universität Erlangen-Nürnberg), Robert Schnabel(University of Pannonia), Grażyna Rydzewska(Ministry of Interior and Administration), Viviana Gerardi(Università Cattolica del Sacro Cuore), Åsa Karlsson(Karlstad University), Jan Kowalski(Statistics Sweden), Franco Scaldaferri(Fondazione Humanitas per la Ricerca), Charlotte Admyre(Karolinska University Hospital), Stuart Bloom(Roche (United Kingdom)), Robert Petryka, Thomas Knittel(University of Göttingen), Robert Löfberg(Karolinska Institutet), Stéphane Nancey
Cited by 73
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease
|Nature Genetics|2017|1.5k
Exosomes with Immune Modulatory Features Are Present in Human Breast Milk
|The Journal of Immunology|2007|1.2k